![Design of CD19 antibody constructs and CD19 targeting strategies. (A)... | Download Scientific Diagram Design of CD19 antibody constructs and CD19 targeting strategies. (A)... | Download Scientific Diagram](https://www.researchgate.net/publication/323651667/figure/fig1/AS:613833534091264@1523360727464/Design-of-CD19-antibody-constructs-and-CD19-targeting-strategies-A-CD19-antibody.png)
Design of CD19 antibody constructs and CD19 targeting strategies. (A)... | Download Scientific Diagram
![Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients | ACS Synthetic Biology Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients | ACS Synthetic Biology](https://pubs.acs.org/cms/10.1021/acssynbio.1c00010/asset/images/large/sb1c00010_0004.jpeg)
Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients | ACS Synthetic Biology
![IJMS | Free Full-Text | A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia IJMS | Free Full-Text | A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia](https://www.mdpi.com/ijms/ijms-22-02150/article_deploy/html/images/ijms-22-02150-g001.png)
IJMS | Free Full-Text | A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia
![Frontiers | Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL Frontiers | Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL](https://www.frontiersin.org/files/Articles/1165870/fimmu-14-1165870-HTML/image_m/fimmu-14-1165870-g001.jpg)
Frontiers | Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL
![A dynamic interaction between CD19 and the tetraspanin CD81 controls B cell co-receptor trafficking | eLife A dynamic interaction between CD19 and the tetraspanin CD81 controls B cell co-receptor trafficking | eLife](https://iiif.elifesciences.org/lax/52337%2Felife-52337-fig5-v2.tif/full/1500,/0/default.jpg)
A dynamic interaction between CD19 and the tetraspanin CD81 controls B cell co-receptor trafficking | eLife
![CD19: a biomarker for B cell development, lymphoma diagnosis and therapy | Experimental Hematology & Oncology | Full Text CD19: a biomarker for B cell development, lymphoma diagnosis and therapy | Experimental Hematology & Oncology | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2F2162-3619-1-36/MediaObjects/40164_2012_Article_34_Fig2_HTML.jpg)
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy | Experimental Hematology & Oncology | Full Text
of CD19 and CD20 expression during B cell development. CD19 expression... | Download Scientific Diagram
![PDF] CD 19 chimeric antigen receptor ( CD 19 CAR )-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin ' s Lymphomas | Semantic Scholar PDF] CD 19 chimeric antigen receptor ( CD 19 CAR )-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin ' s Lymphomas | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/3f53b0ce48344959ad1e51dc7b90a8f034eebf1a/10-Figure1-1.png)
PDF] CD 19 chimeric antigen receptor ( CD 19 CAR )-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin ' s Lymphomas | Semantic Scholar
![Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions: Molecular Therapy - Oncolytics Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions: Molecular Therapy - Oncolytics](https://www.cell.com/cms/attachment/1e2b9ff3-3da0-4a75-a43c-bc887198623e/fx1_lrg.jpg)
Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions: Molecular Therapy - Oncolytics
![Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors | Nature Reviews Clinical Oncology Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors | Nature Reviews Clinical Oncology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fnrclinonc.2013.46/MediaObjects/41571_2013_Article_BFnrclinonc201346_Fig1_HTML.jpg)
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors | Nature Reviews Clinical Oncology
![Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor: Molecular Therapy - Oncolytics Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor: Molecular Therapy - Oncolytics](https://www.cell.com/cms/asset/b90b2fa9-07b6-4619-980c-a83657596e6c/fx1.jpg)